S63845, is the name of the new compound that can help in the fight against breast cancer.
This belongs to a new class of drugs that detect the weaknesses of cancer cells, which can help in the treatment of breast cancer, is the conclusion reached by scientists after a new study published in Science Translational Medicine.
The team of researchers involved in the research, are from the Walter and Eliza Hall Medical Research Institute, and see the breakthrough as a paradigm shift, which can significantly improve the results for some more aggressive forms of breast cancer. This new compound (S63845), combined with standard / base treatment, blocks the Mcl-1 protein, which keeps cancer cells alive. According to James Whittle, a co-author of the study, blocking the protein is crucial because it “allows cancer cells to resist chemotherapy and other anti-cancer treatments”.
The use of this novel compound has been found to be more effective in the so-called “triple negative” and HER2 positive breast cancers. This is the first time that the compound S63845, developed by the pharmaceutical company Servier, has shown to be really effective in the treatment of breast cancer. The results obtained will allow this to continue for research in clinical trials.
“The combination of the S63845 inhibitor with standard therapies was much more effective than any treatment. These can be incredibly aggressive tumors. Seeing a response to combination therapy in this type of tumor is very exciting”, said James Whittle.
This new development was only possible thanks to the support of Victorian Cancer Biobank and samples donated by breast cancer patients, which in turn allowed for the generation of a large number of laboratory models that mimicked the way tumors behaved and responded to Therapy in the patient.
These results are particularly important for the “triple negative” type because, unlike other types of breast cancer, this has not yet seen substantial improvements in treatment or patient outcomes over the past three decades.